Tiziana Life Sciences Publishes Intranasal Foralumab Study
In an open-label study of 10 patients with non-active secondary progressive multiple sclerosis, intranasal foralumab showed no serious or...
Clinical Trial Tests D-Serine to Modify Parkinson’s Disease
SPARK NS and Haukeland University Hospital will run a randomized, double-blind, placebo-controlled Phase 2b trial of oral D-serine in...
Orphai’s LAM-001 Study Selected for ATS 2026 Presentation
No efficacy or safety data were released, but Orphai Therapeutics will present 24-week Phase 2a results of inhaled sirolimus...
Spyglass Pharma Begins Phase III Trials for BIM-IOL System
SpyGlass Pharma has randomized the first patients into two registrational Phase III trials, SGP-005 and SGP-006, evaluating its Bimatoprost...
Rein’s Breakthrough IPF Drug Gets Rare EU Orphan Status
Rein Therapeutics secured European orphan drug designation for LTI-03 in idiopathic pulmonary fibrosis, adding regulatory leverage to a program...
Reunion Unlocks Full RE104 PPD Phase 2 Trial Results
Reunion Neuroscience’s single-dose RE104 met the primary endpoint in the Phase 2 RECONNECT study for postpartum depression (PPD), delivering...
The Seven-Day Miracle: Why the FDA’s New Pathway Could be the End of Randomized Clinical Trials
The parents of Baby K.J. (Kyle Patrick Muldoon, Jr.) didn’t have years to wait for a double-blind, placebo-controlled trial....
FDA Confirms Rexlemestrocel-L Efficacy for Back Pain Relief
Mesoblast’s first randomized Phase 3 trial in chronic discogenic low back pain reported a more than three-fold increase in...
Korea’s Integrated Approach to Clinical Trial Planning: A New Model for Global Sponsors
The sponsor team had expected a slow start in Europe, but they weren’t prepared for how fragmented the process...
Axsome Launches Surging Phase 3 Trial for Fibromyalgia Drug
Axsome has dosed the first patient in FORWARD, a Phase 3 randomized withdrawal trial of AXS-14 (esreboxetine) for fibromyalgia....